2023-03-30 HC Andersen – Orviglance commercial opportunity and progress towards launch Deputy Chief Executive Officer & CCO presents at HC Andersen
2023-02-16 HC Andersen – Q4 2022 highlights and Q&A Chief Executive Officer presents at HC Andersen - Q4 2022 highlights and Q&A
2022-05-31 HC Andersen – Oncology Seminar Chief Executive Officer presents at HC Andersen Oncology Seminar
2022-05-19 Erik Penser Bank – Company Day Chief Executive Officer presents at Erik Pensers Company Day
2022-04-27 Redeye Orphan Drug Day Chief Medical Officer, Carl Bjartmar presents at Redeye Orphan Drug Day
2022-02-24 Erik Penser Bank – Life Science day Chief Commercial Officer Julie Waras Brogren presents at Erik Pensers Life Science day
2022-01-31 Ascelia Pharma – Aktiedagen in Lund 2022 Chief Commercial Officer presents at Aktiedagen in Lund
2022-01-20 Redeye Fight Cancer Seminar 2022 VP of R&D Andreas Norlin presents at Redeye Fight Cancer Seminar
2021-12-07 HC Andersen Capital seminar – Re-read Study Orviglance vs. Gadolinium CEO Magnus Corfitzen presents results from the re-read study vs. a gadolinium contrast agent (presentation in Danish)
2021-11-11 Redeye Life Science Day 2021 Ascelia Pharma CEO Magnus Corfitzen presents at Redeye Life Science Day.
2021-11-04 Q3 2021 Financial Presentation The Executive Managment in Ascelia Pharma presents a business update and the quarterly results
2021-10-06 HC Andersen/Nordea Small & Mid Cap Seminar CEO Magnus Corfitzen presents at the Danish HC Andersen/Nordea Small & Mid cap seminar (presentation in Danish)
2021-09-30 Erik Penser Bank – Orphan Drugs Day CEO Magnus Corfitzen presents how Ascelia Pharma advances orphan drugs
2021-09-28 Swedish Shareholders’ Association CMO Carl Bjartmar presents Ascelia Pharma at the Swedish Shareholders' Association's share day
2021-09-27 Clinical collaboration with Taiho Oncology CEO Magnus Corfitzen presents the clinical collaboration with Taiho Oncology (in Danish)